Kairos Pharma Ltd. (NYSE American: KAPA) announced positive interim efficacy data from its ongoing Phase 2 trial evaluating ENV-105 in combination with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). The analysis revealed a statistically significant difference in progression-free survival (PFS), with a median PFS of 17.7 months for patients receiving ENV-105 plus apalutamide compared to just two months for those receiving apalutamide alone (P=0.0008). This dramatic difference underscores the potential of ENV-105 to address a critical unmet need in prostate cancer treatment.
The implications of this announcement are substantial. ENV-105 is an antibody that targets CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By reversing drug resistance and restoring the effectiveness of standard therapies, ENV-105 could significantly extend the lives of patients with mCRPC, a deadly form of prostate cancer that has spread to other parts of the body and no longer responds to hormone therapy. The interim data suggest that adding ENV-105 to apalutamide not only delays disease progression but may also re-sensitize tumors to treatment, offering a new avenue for patients who have exhausted other options.
In response to these encouraging results, Kairos Pharma has modified the Phase 2 protocol to enroll patients earlier in disease progression. Specifically, patients who experience a PSA increase following upfront treatment with an androgen signaling inhibitor will be randomized to receive either enzalutamide alone or enzalutamide in combination with ENV-105. This change is intended to expand the eligible patient population and facilitate enrollment, with completion of the Phase 2 trial targeted in or before the fourth quarter of 2027. The protocol amendment reflects the company's confidence in ENV-105 and its commitment to accelerating development.
For investors, the positive interim data and the strategic protocol modification could signal a significant near-term catalyst for Kairos Pharma. The company, based in Los Angeles, California, is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Its lead candidate, ENV-105, aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. If the final Phase 2 results confirm the interim findings, ENV-105 could become a cornerstone of combination therapy for mCRPC, potentially driving substantial revenue growth.
The broader impact on the prostate cancer treatment landscape could be profound. With limited options for patients who progress on androgen signaling inhibitors, a therapy that significantly improves PFS could quickly gain traction among oncologists. Moreover, the mechanism of action of ENV-105—targeting CD105 to overcome resistance—may be applicable to other cancers where CD105 plays a role, opening up additional indications. This positions Kairos Pharma as a potential leader in the fight against drug-resistant cancers.
To view the full press release, visit https://ibn.fm/EDpxx. The latest news and updates relating to KAPA are available in the company's newsroom at https://ibn.fm/KAPA. For more information about Kairos Pharma, visit Kairos Pharma (NYSE American: KAPA).
BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. The platform delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of followers, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team, BioMedWire serves private and public companies seeking to reach investors, influencers, consumers, journalists, and the general public. For more information, visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
